High Pretreatment LDH Predicts Poor Prognosis in Hypopharyngeal Cancer

Jialing Wu†, Kaiyun You†, Changlong Chen†, Huimin Zhong, Yanhui Jiang, Huaqian Mo, Juanjuan Song, Xingsheng Qiu* and Yimin Liu*

Department of Radiation Oncology, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, China

Background: Elevated pretreatment lactate dehydrogenase (LDH) has been associated with poor prognosis in various malignancies; however, its prognostic role in hypopharyngeal cancer remains elusive. In this study, we aimed to assess the association between pretreatment LDH and clinical outcome of hypopharyngeal cancer.

Methods: We retrospectively collected 198 hypopharyngeal cancer patients treated with surgery in our institution between 2004 and 2018. The prognostic role of pretreatment LDH was explored by using univariate and multivariate analyses. Besides, subgroup analysis was performed based on T stage.

Results: Three-year and Five-year of disease-free survival (DFS, 67.0 vs 57.4%, 65.8 vs 39.8%, p = 0.007) and overall survival (OS, 74.8 vs 68.9%, 66.8 vs 50.8%, p = 0.006) exhibited significant differences between low LDH level and high LDH level groups. Univariate analysis showed that pretreatment elevated serum LDH served as an unfavorable determinant with regard to DFS and OS. Further multivariate analysis also confirmed that LDH was an independent predictor for DFS and OS. Additionally, N status and age were also found to be significantly associated with both DFS and OS.

Conclusion: Pretreatment elevated serum LDH is an inferior prognostic factor for patients with hypopharyngeal cancer. These results should be validated by more multicenter and prospective studies.

Keywords: lactate dehydrogenase (LDH), hypopharyngeal cancer, prognosis, retrospective, T3–4

INTRODUCTION

Among head and neck squamous cell carcinomas, hypopharyngeal cancer is comparatively uncommon and aggressive (1). Hypopharyngeal cancer occurs predominantly in males (2) with heavy alcohol consumption and tobacco use (3). It is mainly arising from pyriform sinus, and early symptoms of this malignancy are often neglected, which contributes to the fact that hypopharyngeal cancer patients usually present with an advanced stage at their first diagnosis (4, 5). Therefore, despite advancements in diagnosis and treatment modalities, the 5-year disease-free survival (DFS) rate and overall survival (OS) rate of hypopharyngeal cancer remain unsatisfied, which were in the range of 35.8–65.5% and 26.9–58.5%, respectively, according to different studies (6–14).
Surgery is one of the main initial treatment options. The surgery modality for locally advanced hypopharyngeal cancer is pharyngectomy with total or partial laryngectomy, in conjunction with selective or radical neck dissection, with reasonable adjuvant treatment based on the presence of clinical adverse pathologic features (15). Given the poor prognosis of advanced hypopharyngeal cancer, a novel prognostic determinant that can accurately predict clinical outcomes for these patients is urgently needed.

Lactate dehydrogenase (LDH) is a glycolytic enzyme (16), comprised of four polypeptide subunits, in charge of the transformation of pyruvate into lactate in aerobic conditions (17). Distinguish from non-proliferating cells, which are dominated by mitochondrial tricarboxylic acid (TCA) cycle to generate ATP needed for cellular activities, a majority of cancer cells are alternatively characterized by aerobic glycolysis, a phenomenon called “the Warburg effect.” To better understand Warburg effect, we should note that proliferating cells have more crucial metabolic requirements beyond ATP, such as carbon and NADPH, which are needed for macromolecular synthesis like nucleotides, amino acids, and lipids. Despite the inefficient ATP production of aerobic glycolysis, the superiority it conferred to cancer cells is the robust generation of NADPH and excretion of excess carbon. The enzyme LDH is the main player in the conversion of both glucose and glutamine to lactate, and one by-product of the conversion is the generation of NADPH (18). The inhibition of LDH resulted in reduced cell proliferation (19).

Former research studies showed that LDH not merely associates with the activation of some proto-oncogenes, such as Myc and HIF-α (20), but also plays a crucial role in the maintenance of tumor invasiveness (21, 22), metastatic potential (23, 24), chemoresistance (25), and radioresistance (26). Moreover, it also showed that LDH takes part in immunosuppression (27), and LDH can be regarded as an immune surveillance prognostic marker (28) and its abnormal rise was forerunner of unfavorable outcomes in cancer patients (29).

The prognostic significance of pretreatment serum LDH in multiple malignancies is well established, such as biliary tract cancer (30), lung cancer (31, 32), breast cancer (33), gastric cancer (34), colorectal cancer (35), and so on (36). However, the clinical significance of LDH in hypopharyngeal cancer is quite unclear, and it is worthwhile to explore the prognostic role of LDH. Serum LDH is promising to become a cost effective, non-invasive, and easily reproducible marker, which can predict survival outcomes in hypopharyngeal cancer. Therefore, it is imperative to evaluate whether LDH can serve as a prognostic factor in hypopharyngeal cancer patients.

MATERIALS AND METHODS

Patients

We retrospectively reviewed patients diagnosed with hypopharyngeal cancer between March 2004 and December 2018 in our institution (Sun Yat-Sen Memorial hospital). Exclusion criteria included: initial definitive chemoradiotherapy, no available pretreatment serum LDH, inadequate follow-up, data and renunciation of medical treatment. We enrolled the patients treated with surgery and with eligible pretreatment serum LDH. Overall, we collected 198 histologically confirmed hypopharyngeal cancer patients in this study. Patients’ baseline clinical and pathological characteristics, including age, gender, tumor differentiation, surgical margin, vascular invasion, adjuvant therapy, type of surgery, adjuvant radiotherapy, chemotherapy regimen and cycles, T stage and N status were collected and analyzed. This study was performed under the review and approval of the Institutional Review Board at Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University.

Laboratory Testing of LDH

Peripheral blood samples were collected and analyzed for laboratory tests within 2 weeks before the beginning of treatment. Serum LDH levels were measured employing a Hitachi Automatic Analyzer 7600-020 (Hitachi High-Technologies, Tokyo, Japan). Normal serum LDH enzyme levels were defined to 108–252 U/L. Based on pretreatment serum LDH levels, patients were classified into high LDH group (LDH ≥178 U/L) and low LDH group (LDH <178 U/L) (37).

Clinical Staging

All patients underwent pretreatment evaluations, including: physical examinations, hematologic and biochemical tests, chest radiography, electronic laryngoscope, esophageal barium meal examination. Contrast-enhanced magnetic resonance imaging (MRI) or computed tomography (CT) of the head and neck was performed on 64 and three patients, respectively. MRI and CT scan were aimed to evaluate the size and surrounding invasion of the tumor, as well as the status of lymph node metastasis. Abdominal ultrasonography and whole body bone scan using single-photon emission computed tomography (SPECT), which was used to detect distant metastasis, were carried out in 143 and 85 patients, respectively.

The TNM classification of all patients were staged according to the 7th edition of the American Joint Committee on Cancer (AJCC) for hypopharyngeal cancer.

Treatment of Patients

All of the patients received surgery with or without adjuvant therapy. Treatment option was decided upon thorough evaluation and made by a multidisciplinary team, regarding treatment efficacy, function maintenance and complication. Surgery modality including excision of hypopharyngeal cancer in the absent of neck dissection, pharyngectomy with total or partial laryngectomy, in conjunction with radical, modified radical, selective or extended neck dissection. According to the guideline proposed by the American Head and Neck Society (38) for patients with hypopharyngeal cancer, (1) radical neck dissection referred to ipsilateral cervical lymphadenectomy of levels I–V, (2) modified radical neck dissection spared one or more non-lymphatic structures, (3) lymph nodes in levels II–IV were removed in selective neck dissection, (4) removal of structures not contained in radical neck dissection termed
extended neck dissection. Alterations could be made depending on the sophisticated clinical circumstances.

Adjuvant treatment was carried out based on the presence of clinical adverse pathologic features such as extranodal extension, positive margin, pT3 or pT4 primary, multiple positive lymph nodes, perineural invasion and lymphatic invasion. 119 (60.1%) patients were prescribed with adjuvant chemotherapy; regimen of TP (taxol and platinum) (73.1%) was the most commonly used regimen in this population. Other chemotherapeutic schemes included TPF (taxol, platinum and 5-fluorouracil) and PF (platinum and 5-fluorouracil). For advanced hypopharyngeal cancer patients with adverse pathologic features, postoperative radiotherapy, either 3D conformal RT or IMRT was performed. The range of total prescribed radiation doses was 60–66 Gy for tumor bed, and 50–56 Gy for lymphatic drainage area (2.0 Gy/fraction; daily Monday–Friday; in 6–7 weeks).

Follow-Up Evaluation
After the completion of surgery and adjuvant therapy, patients were followed up every 3 months for the first 2 years, semiannually for the subsequent 3 years, and annually thereafter. The observation of follow-up included physical examination, esophagography, chest X-ray, MRI of hypopharynx and neck. Overall survival (OS) was defined as the time interval from the beginning of treatment to death. Disease-free survival (DFS) was the time from the initiation of therapy to recurrence or death of any cause. Locoregional recurrence-free survival (LRFS) was the duration between the beginning of treatment and the first local recurrence or regional lymph node metastasis. Distant metastasis-free survival (DMFS) was defined as the duration from the date treatment began to the time of distant metastasis.

Statistical Analysis
Data statistical analysis was carried out by employing SPSS 20.0 software. We chose the median level of LDH to separate all the patients into two groups. The correlation between categorical variables and clinical outcomes (DFS and OS) was analyzed by chi-square test. Kaplan–Meier method was used to evaluate survival distribution (DFS and OS), and the log-rank test was performed to calculate the significant differences of survival between groups. Univariate and multivariate Cox proportional hazard regression model was employed to further find out the risk factors for DFS and OS. Patients’ clinical characteristics including age, gender, T stage, N status, tumor differentiation, surgical margin, vascular invasion, and adjuvant chemotherapy were included as covariates in multivariate analysis. Multivariate analysis was carried out by forward stepwise regression procedure. A two-sided P-value ≤0.05 was deemed statistically significant.

RESULTS
Baseline Characteristics
The clinical characteristics of 198 eligible patients diagnosed with hypopharyngeal cancer and underwent surgery were retrospectively collected and evaluated. The median follow-up time was 4.63 years (range: 0.58–13.17 years). All of the patients were divided into two groups: low LDH group (≤178 U/L) and high LDH group (>178 U/L). Among these 198 patients, 193 were males and five were females, with a median age of 58 years (range: 36–79 years). Squamous cell carcinoma was the most common histology, and the rest were carcinosarcoma and sarcoma. With regard to histologic grade, the number of well differentiated and poorly differentiated was 163 and 35, respectively. 167 (84.3%) patients had a history of heavy cigarette smoking, and 115 (58.1%) patients were heavy drinkers. According to the 7th edition TNM cancer staging system of AJCC, 185 (93.4%) patients were presented at stages III–IV, 52 (26.3%) patients were diagnosed with T1–2 stage, and 146 (73.7%) patients were diagnosed with T3–4 stage. With regard to lymph node metastasis status, the patient numbers of N0–1 and N2–3 were 75 (37.9%) and 123 (62.1%) respectively. Patients’ clinical and pathological characteristics are presented in Table 1.

Prognostic Role of Pretreatment Serum LDH for the Whole Group
Survival analysis showed that three- and five-year of DFS (67.0 vs. 57.4%, 65.8 vs. 39.8%, p = 0.007) and OS (74.8 vs. 68.9%, 66.8 vs. 51.8%, p = 0.003) of patients with high LDH were statistically less favorable than the low LDH patients. The log-rank test was also significant for DFS (67.0 vs. 57.4%, p = 0.007) and OS (74.8 vs. 68.9%, p = 0.003) between low and high LDH. In multivariate analysis, age, gender, T stage, N status, tumor differentiation, surgical margin, vascular invasion, and adjuvant chemotherapy were included as covariates in multivariate analysis. The log-rank test was also significant for DFS (67.0 vs. 57.4%, p = 0.007) and OS (74.8 vs. 68.9%, p = 0.003) between low and high LDH. In multivariate analysis, age, gender, T stage, N status, tumor differentiation, surgical margin, vascular invasion, and adjuvant chemotherapy were included as covariates in multivariate analysis. Multivariate Cox proportional hazard regression model was employed to further find out the risk factors for DFS and OS. Patients’ clinical characteristics including age, gender, T stage, N status, tumor differentiation, surgical margin, vascular invasion, and adjuvant chemotherapy were included as covariates in multivariate analysis. Multivariate analysis was carried out by forward stepwise regression procedure. A two-sided P-value ≤0.05 was deemed statistically significant.

TABLE 1 | Baseline characteristics of patients with pretreatment serum LDH ≤ and >178 U/L.

| Variable | Low level of LDH (N = 101) | High level of LDH (N = 97) | P value |
|----------|----------------------------|----------------------------|---------|
| Age, year |                            |                            |         |
| <60      | 63                         | 53                         | 0.269   |
| ≥60      | 38                         | 44                         |         |
| Gender   |                            |                            | 0.684   |
| male     | 98                         | 96                         |         |
| female   | 3                          | 2                          |         |
| T stage* |                            |                            | 0.706   |
| T1       | 8                          | 4                          |         |
| T2       | 21                         | 19                         |         |
| T3       | 31                         | 31                         |         |
| T4       | 41                         | 43                         |         |
| N status*|                            |                            | 0.082   |
| N0–1     | 44                         | 31                         |         |
| N2–3     | 57                         | 66                         |         |
| TNM stage*|                           |                            | 0.100   |
| I        | 3                          | 1                          |         |
| II       | 3                          | 6                          |         |
| III      | 24                         | 12                         |         |
| IV       | 71                         | 78                         |         |
| Tumor differentiation | | | 0.122 |
| well differentiated | 79 | 84 |         |
| poor differentiated | 22 | 13 |         |
| Surgical margin | | | 0.937 |
| positive | 7 | 7 |         |
| negative | 94 | 90 |         |
| Vascular invasion | | | 0.444 |
| yes | 14 | 10 |         |
| no | 87 | 87 |         |
| Adjuvant chemotherapy | | | 0.931 |
| yes | 61 | 58 |         |
| no | 40 | 39 |         |

LDH, lactate dehydrogenase; TNM, tumor-node-metastasis.
*Tumor-node-metastasis staging system proposed by the 7th edition American Joint Committee on Cancer (AJCC).
vs. 50.8%, \( p = 0.006 \)) exhibited significant difference between low LDH and high LDH groups (Table 2). Additionally, three- and five-year of LRFS (low vs. high, 73.7 vs. 64.9%, 72.6 vs. 53.1%, \( p = 0.024 \)) and DMFS (low vs. high, 84.2 vs. 79.9%, 81.5 vs. 60.6%, \( p = 0.039 \)) also proved a significant difference between groups (Table 3). The Kaplan–Meier curves for OS and DFS for patients with LDH ≤178 U/L and LDH >178 U/L are presented in Figures 1, 2.

Univariate and multivariate analyses were performed to evaluate the relationship between clinicopathologic variables and survival outcomes. According to univariate analysis, high pretreatment serum LDH served as an unfavorable determinant with regard to DFS (low vs. high, \( p = 0.008 \); HR = 0.566, 95% CI 0.372–0.863) and OS (low vs. high, \( p = 0.007 \); HR = 0.560, 95% CI 0.366–0.856). Additionally, age was also proven to be correlated significantly with both DFS and OS, and N status was correlated with DFS. However, gender, T stage, tumor differentiation, surgical margin, and so on were not associated with survival prognosis (Table 4). Moreover, multivariate analysis further revealed that LDH (low vs. high, DFS, \( p = 0.0031 \); HR = 0.628, 95% CI 0.410–0.959; OS, \( p = 0.023 \); HR = 0.608, 95% CI 0.397–0.933), N status (N0–1 vs. N2–3, DFS, \( p = 0.005 \); HR = 0.517, 95% CI 0.324–0.823; OS, \( p = 0.035 \); HR = 0.611, 95% CI 0.387–0.967) and age (<60 vs. ≥60, DFS, \( p = 0.007 \); HR = 0.562, 95% CI 0.369–0.857; OS, \( p = 0.014 \); HR = 0.586, 95% CI 0.383–0.897) were independent prognostic factors for both DFS and OS (Table 5).

### TABLE 2 | Survival analysis for all the patients with pretreatment serum LDH ≤ and > 178 U/L.

| Group                  | Low level of LDH (N = 101) | High level of LDH (N = 97) | P value |
|------------------------|-----------------------------|-----------------------------|---------|
|                        | 3-year         | 5-year        | 3-year       | 5-year       |         |
| DFS                    | 67.0%          | 65.8%         | 57.4%        | 39.8%        | 0.007   |
| OS                     | 74.8%          | 66.8%         | 68.9%        | 50.8%        | 0.006   |

LDH, lactate dehydrogenase; DFS, disease-free survival; OS, overall survival.

### TABLE 3 | Recurrence Patterns for all the patients with pretreatment serum LDH ≤ and > 178 U/L.

| Group                  | Low level of LDH (N = 101) | High level of LDH (N = 97) | P value |
|------------------------|-----------------------------|-----------------------------|---------|
|                        | 3-year         | 5-year        | 3-year       | 5-year       |         |
| LRFS                   | 73.7%          | 72.6%         | 64.9%        | 53.1%        | 0.024   |
| DMFS                   | 84.2%          | 81.5%         | 79.9%        | 60.6%        | 0.039   |

LDH, lactate dehydrogenase; LRFS, local recurrence-free survival; DMFS, distant metastasis-free survival.

### FIGURE 1 | Kaplan–Meier curve for overall survival, stratified by pretreatment serum LDH ≤178 U/L and >178 U/L. Log-rank test, \( P < 0.05 \).

### FIGURE 2 | Kaplan–Meier curve for disease-free survival, stratified by pretreatment serum LDH ≤178 U/L and >178 U/L. Log-rank test, \( P < 0.05 \).

### FIGURE 3 | Kaplan–Meier curve for overall survival, stratified by pretreatment serum LDH ≤178 U/L and >178 U/L. Log-rank test, \( P < 0.05 \).

### DISCUSSION

Among LDH family members, LDH-5, consisting LDHA subunit only, is the one that has the most vigorous capacity to catalyze pyruvate into lactic acid. Despite the availability of oxygen and the much less ATP produced, cancer cells prevailingly convert into aerobic glycolysis, which contributes to the synthesis of the substrates needed for cancer cell proliferation. Liang S et al. reported that Phosphoenolpyruvate carboxykinase 1 (PCK1)
inhibited LDHA expression and thus impeded tumor cells’ growth and metastasis (39). In nasopharyngeal carcinoma, JMJD2A was predicted to boost the Warburg effect through LDHA activation, and fuel tumorigenesis and progression ultimately (40). Jiujie C et al. discovered that FOXM1 and LDHA were overexpressed simultaneously in pancreatic cancer. FOXM1 upregulated LDHA expression by promoting its transcription and was further attributed to pancreatic cancer cell proliferation and metastasis (41). The previous findings of LDH demonstrated the important impact of LDH on tumor development, and therefore, the clinical significance of LDH in cancer merits further investigation.

Elevated serum LDH has long been regarded as an adverse prognostic factor in various malignancies (36). Faloppi L et al.

**TABLE 4 | Univariate analysis of DFS and OS for the Whole Group.**

| Variable          | DFS HR(95%CI) | DFS P value | OS HR(95%CI) | OS P value |
|-------------------|---------------|-------------|--------------|------------|
| Age, year         |               |             |              |            |
| <60 vs ≥60        | 0.612(0.406–0.925) | 0.020       | 0.623(0.411–0.944) | 0.026      |
| Gender            |               |             |              |            |
| Male vs female    | 3.079(0.429–22.102) | 0.263       | 2.941(0.410–21.113) | 0.283      |
| LDH level         |               |             |              |            |
| Low vs high       | 0.566(0.372–0.863) | 0.008       | 0.560(0.366–0.856) | 0.007      |
| T stage           |               |             |              |            |
| T1–2 vs T3–4      | 1.017(0.638–1.621) | 0.945       | 1.057(0.657–1.700) | 0.820      |
| N status          |               |             |              |            |
| N0–1 vs N2–3      | 0.550(0.349–0.867) | 0.010       | 0.647(0.414–1.011) | 0.056      |
| Tumor differentiation |           |             |              |            |
| Well vs poorly    | 1.076(0.627–1.847) | 0.789       | 0.972(0.566–1.669) | 0.919      |
| Surgical margin   |               |             |              |            |
| Positive vs negative | 0.973(0.643–1.472) | 0.897       | 0.969(0.641–1.467) | 0.883      |
| Vascular invasion |               |             |              |            |
| Yes vs no         | 1.328(0.999–1.767) | 0.051       | 1.135(0.827–1.556) | 0.433      |
| Adjuvant chemotherapy |       |             |              |            |
| Yes vs no         | 1.353(0.882–2.075) | 0.166       | 1.401(0.909–2.159) | 0.126      |

LDH, lactate dehydrogenase; DFS, disease-free survival; OS, overall survival; CI, confidence interval; HR, hazard ratio.

**TABLE 5 | Multivariate analysis of DFS and OS for all the patients.**

| Variable          | DFS HR(95%CI) | DFS P value | OS HR(95%CI) | OS P value |
|-------------------|---------------|-------------|--------------|------------|
| LDH low vs high   | 0.628(0.410–0.959) | 0.031       | 0.608(0.397–0.933) | 0.023      |
| N status N0–1 vs N2–3 | 0.517(0.324–0.823) | 0.005       | 0.611(0.387–0.967) | 0.035      |
| Age, year <60 vs ≥60 | 0.562(0.369–0.857) | 0.007       | 0.586(0.383–0.897) | 0.014      |

LDH, lactate dehydrogenase; DFS, disease-free survival; OS, overall survival; CI, confidence interval; HR, hazard ratio.

**TABLE 6 | Survival analysis for patients with T1–2.**

| Group            | Low level of LDH (N = 29) | High level of LDH (N = 23) | P value |
|------------------|----------------------------|-----------------------------|---------|
|                  | 3-year | 5-year | 3-year | 5-year |         |
| DFS              | 69.0%  | 64.4%  | 65.2%  | 39.5%  | 0.345   |
| OS               | 71.6%  | 62.0%  | 69.8%  | 45.2%  | 0.397   |

LDH, lactate dehydrogenase; DFS, disease-free survival; OS, overall survival; CI, confidence interval; HR, hazard ratio.

**TABLE 7 | Survival analysis for patients with T3–4.**

| Group            | Low level of LDH (N = 72) | High level of LDH (N = 74) | P value |
|------------------|----------------------------|-----------------------------|---------|
|                  | 3-year | 5-year | 3-year | 5-year |         |
| DFS              | 66.3%  | 66.3%  | 55.0%  | 40.3%  | 0.012   |
| OS               | 76.0%  | 68.5%  | 68.7%  | 52.7%  | 0.008   |

LDH, lactate dehydrogenase; DFS, disease-free survival; OS, overall survival.

**TABLE 8 | Multivariate analysis of DFS and OS for patients with T3–4.**

| Variable          | DFS HR(95%CI) | DFS P value | OS HR(95%CI) | OS P value |
|-------------------|---------------|-------------|--------------|------------|
| LDH low vs high   | 0.590(0.359–0.971) | 0.038       | 0.516(0.313–0.848) | 0.009      |
| N status N0–1 vs N2–3 | 0.491(0.282–0.853) | 0.012       | NA           | NA         |
| Age, year <60 vs ≥60 | 0.516(0.316–0.844) | 0.008       | NA           | NA         |

LDH, lactate dehydrogenase; DFS, disease-free survival; OS, overall survival.
suggested that high pretreatment serum LDH levels significantly associated with poor clinical outcomes in biliary tract cancer patients receiving first-line chemotherapy (30). Pelizzari G et al. reported that during first-line treatment in metastatic breast cancer patients, elevated serum LDH levels served as independent ominous prognostic factor for PFS (33). Additionally, several meta-analysis studies revealed that elevated pretreatment serum LDH was an inferior factor in metastatic prostate cancer (42), osteosarcoma (43), urothelial carcinoma (44), breast cancer (45) and nasopharyngeal carcinoma (46). Moreover, in addition to serving as a prognostic factor, serum LDH also emerges as an indicator of treatment option. Previous studies found that serum LDH was able to benefit from TORC1 inhibition temsirolimus (47), and identify locally advanced cervical cancer patients who could take advantage of neoadjuvant chemotherapy (37). Nevertheless, the reports about LDH value in hypopharyngeal cancer is scarcely any.

Hypopharyngeal cancer is a head and neck squamous cell carcinoma, predominantly debuted with advanced stage and accompanied with poor oncologic outcomes. To our best information, our study, for the first time, evaluated the prognostic impact of pretreatment serum LDH in hypopharyngeal cancer patients who underwent primary surgery, and the results confirmed that high level of LDH was an inferior factor in terms of DFS (low vs. high, p = 0.008; HR = 0.566, 95% CI 0.372–0.863) and OS (low vs. high, p = 0.007; HR = 0.560, 95% CI 0.366–0.856).

More importantly, our results showed that the significant correlation between LDH and survival outcomes was present specifically in T3–4 patients, rather than in T1–2 patients. Additionally, multivariate analysis of DFS and OS for patients with T3–4 showed that LDH was an independent prognostic factor for both DFS (low vs. high, p = 0.038; HR = 0.590, 95% CI 0.359–0.971) and OS (low vs. high, p = 0.009; HR = 0.516, 95% CI 0.313–0.848). Besides, multivariate analysis also disclosed that N2–3 and age ≥60 were correlated with worse prognosis, and these results were consistent with previous study (15, 48, 49). Based on the findings above, patients with high LDH, N2–3 and age ≥60 tend to experience worse survival outcomes, and this group of patients may need to adopt more intensive follow-up care.

One former study showed that prognostic nutritional index (PNI) played an important role in predicting survival outcomes in hypopharyngeal cancer patients who received surgery; however, the population enrolled in this study was relatively small (48). Recent studies also looked into inflammation index such as NLR and CPR (50, 51). The superior role of NLR, CPR, and LDH in predicting survival was controversial; nevertheless, it may be of great value to incorporate the parameters above in evaluating hypopharyngeal cancer patients prognosis (52, 53).

Nasopharyngeal cancer (NPC) is another head and neck cancer that affects the throat, and the role of LDH in nasopharyngeal cancer had been exhaustively evaluated. Jun M et al. reported that high baseline LDH levels were related with advanced stage and served as an inferior predictor for OS, DFS, and DMFS for NPC patients. Patients with elevated LDH levels may benefit from more aggressive treatment modalities (54). However, Ming-huang H et al. found that LDH was too, a poor predictor for local relapse-free in survival NPC patients (55). For metastatic NPC patients, elevated LDH also was an adverse prognostic factor (56). Moreover, longitudinal variation of serum LDH predicted chemotherapy response in metastatic NPC (57). In addition, prognostic nomogram incorporating LDH and other variables showed satisfactory efficacy in predicting OS of NPC patients (58, 59).

Meanwhile, our study still has certain limitations. First, the present study was performed retrospectively, and therefore, more prospective studies are urgently desired to validate our analysis. Second, the cut-off LDH value was to define the higher LDH level; however, different institutions may have various parameters, which limit the utility of this LDH cut-off value. For patients with advanced disease, concurrent cisplatin-based chemotherapy and radiotherapy is recommended (60), for having equivalent treatment efficacy and maintaining larynx function intact compared to surgery (10–12, 61, 62). However, with radical surgery as the major treatment modality in our institution, the present study failed to investigate LDH prognostic value in patients who received definitive chemoradiotherapy as their initial treatment option. Moreover, our study did not evaluate the expression level of LDHA in tumor samples. Further investigation of the expression levels of LDHA in tumor tissues, its relation with serum LDH, and the clinical significance is warranted. Besides, we noticed significantly low incidence rate (2.5%) of female hypopharyngeal cancer patients during the data collecting process. In contrast, the incidences of female hypopharyngeal cancer in America (16.3–20%) were reported to be higher than that in our study (1, 63). However, our data regarding the low incidence of female patients was supported by other studies carried out in China, Japan, and Korea (1.6–6.2%) (48, 61, 64). Therefore, our results and conclusions may have limited utility for the female population. Above all, our study shed some light on LDH clinical utility in predicting hypopharyngeal cancer patients’ oncological outcomes.

**CONCLUSIONS**

Pretreatment serum LDH is an independent prognostic factor in hypopharyngeal cancer patients who underwent primary surgery. High pretreatment serum LDH predicts poor prognosis. Patients with high LDH, N2–3 and age ≥60 are inclined to experience worse survival outcomes. Therefore, more intensive follow-up care should be given to these patients.

**DATA AVAILABILITY STATEMENT**

The data analyzed in this study is subject to the following licenses/restrictions: institutional data constrained by IRB. Requests to access these datasets should be directed to liuyimincn@139.com.
REFERENCES

1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jamal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: Cancer J Clin (2018) 68(6):394–424. doi: 10.3322/caac.21492

2. Siegel RL, Miller KD, Jamal A. Cancer statistics, 2020. CA: Cancer J Clin (2020) 70(1):7–30. doi: 10.3322/caac.21590

3. Hashim D, Genden E, Posner M, Hashibe M, Boffetta P. Head and neck cancer prevention: from primary prevention to impact of clinicians on reducing burden. Ann Oncol: Off J Eur Soc Med Oncol (2019) 30(5):744–56. doi: 10.1093/annonc/mdz084

4. Ho AS, Kim S, Tighiouart M, Gudino C, Mita A, Scher KS, et al. Association of Quantitative Metastatic Lymph Node Burden With Survival in Hypopharyngeal and Laryngeal Cancer. JAMA Oncol (2018) 4(7):985–9. doi: 10.1001/jamaoncol.2017.3852

5. Deng XY, Su Y, Zheng L, Xie CM, Gu MF, Zeng RF, et al. Analysis of cervical and retropharyngeal lymph node metastases in the patients with hypopharyngeal carcinoma with computed tomography and magnetic resonance imaging. Chin J Cancer (2010) 29(2):189–93. doi: 10.3732/jcj.09.0298

6. Krishnamrtya M, Katak AC, Sharma JD, Baiyha N, Rahman T, Bhattacharya M, et al. A Survival Analysis of Hypopharyngeal Laryngeal Cancer Patients: A Hospital-Cancer registry Based Study. Indian J Otolaryngol Head Neck Surgery: Off Publ Assoc Otolaryngolologists India (2019) 71(Suppl 1):798–804. doi: 10.1007/s12070-018-1556-4

7. Jakobsen KK, Wingstrand VL, Jensen JS, Grennhoj C, Jensen DH, Karnov K, et al. Incidence and survival of hypopharyngeal cancer: a Danish Nationwide Study from 1980 to 2014. Acta Oncol (Stockholm Sweden) (2019) 58 (11):1570–6. doi: 10.1080/02841869.2019.1657585

8. Hochfelder CG, McGinn AP, Mehta V, Castellucci E, Kabartiti R, Oj TW. Treatment sequence and survival in locoregionally advanced hypopharyngeal cancer: A surveillance, epidemiology, and corresponding treatment strategies post-surgical resection. Cancer Lett (2015) 395:118–24. doi: 10.1016/j.canlet.2014.12.035

9. Petersen JF, Timmermans AJ, van Dijk BAC, Overbeek LIH, Smit LA, Hilgers FJM, et al. Trends in treatment, incidence and survival of hypopharynx cancer: a 20-year population-based study in the Netherlands. Eur Arch Oto Rhino Laryng: Off J Eur Fed Oto Rhino Laryngol Societies (EUFOS): Affiliated German Soc Oto Rhino Laryngol - Head Neck Surg (2018) 275(3):181–9. doi: 10.1007/s00405-017-4766-6

10. Chung EF, Jeong WJ, Torre LA, Jamal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: Cancer J Clin (2018) 68(6):394–424. doi: 10.3322/caac.21492

11. Su X, He HC, Ye ZL, Zhou DL, Liu Q, Yang XH, et al. A 10-Year Study on Larynx Preservation Compared With Surgical Resection in Patients With Locally Advanced Laryngeal and Hypopharyngeal Cancers. Front Oncol (2020) 10:53893. doi: 10.3389/fonc.2020.53893

12. Iwae S, Fujiwara S, Hasegawa T, Ohkami K, et al. Matched-pair analysis of patients with advanced hypopharyngeal cancer: surgery versus concomitant chemoradiation therapy. Int J Clin Oncol (2017) 22(6):1001–8. doi: 10.1007/s10147-017-1151-9

13. Rodrigues J, Breda E, Monteiro E. Surgically-Treated Locoregionally Advanced Hypopharyngeal Cancer: Outcomes. Int Arch Oto Rhino Laryng (2018) 22(4):443–8. doi: 10.1055/s-0038-1641562

14. Lo WC, Wu CT, Wang CP, Yang TL, Lou PJ, Ko JY, et al. Lymph Node Ratio Predicts Recurrence and Survival for Patients with Resectable Stage 4 Hypopharyngeal Cancer. Ann Surg Oncol (2017) 24(6):1707–13. doi: 10.1245/s10434-017-5770-1

15. Heng Y, Zhu Z, Zhou L, Zhang M, Zhou H, Tao L. The presence of risk factors and corresponding treatment strategies post-surgical resection in stage IV hypopharyngeal squamous cell carcinoma patients: a retrospective cohort study. Ann Trans Med (2020) 8(5):189. doi: 10.21037/atm.2020.01.102

16. Augoff K, Hryniewicz-Jankowska A, Tabola R. Lactate dehydrogenase 5: an old friend and a new hope in the war on cancer. Cancer Lett (2015) 358(1):1–7. doi: 10.1016/j.canlet.2014.12.035

17. Swiderk K, Tuñoń I, Martí S, Moliner V. Protein Conformational Landscapes and Catalysis. Influence of Active Site Conformations in the Reaction Catalyzed by L-Lactate Dehydrogenase. ACS Catalysis (2015) 5(4):1172–85. doi: 10.1021/cs501704f

18. Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Sci (New York NY) (5930) 2009 324:1029–33. doi: 10.1126/science.1160809

19. Yeung C, Gibson AE, Issaq SH, Oshima N, Baumgart JT, Edessa LD, et al. Targeting Glycolysis through Inhibition of Lactate Dehydrogenase Impairs Tumor Growth in Preclinical Models of Ewing Sarcoma. Cancer Res (2019) 79 (19):5060–73. doi: 10.1158/0008-5472.Can-19-0217

20. Sanganova I, Cohen IJ, Vemuri K, Shindo M, Maeda M, Mane M, et al. LDH-A regulates the tumor microenvironment via HIF-signaling and modulates the immune response. PLoS One (2018) 13(9):e0203965. doi: 10.1371/journal.pone.0203965

21. Koukourakis MI, Giatromanolaki A, Sivridis E, Gatter KC, Harris AL. Lactate dehydrogenase 5 expression in operable colorectal cancer: strong association with survival and activated vascular endothelial growth factor pathway—a report of the Tumour Angiogenesis Research Group. J Clin Oncol: Off J Am Soc Clin Oncol (2006) 24(26):4301–8. doi: 10.1200/jco.2006.05.9501

22. Azuma M, Shi M, Danenberg KD, Gardner H, Barrett C, Jacques CJ, et al. Serum lactate dehydrogenase levels and glycolysis significantly correlate with tumor VEGF and VEGFR expression in metastatic CRC patients. Pharmacogenomics (2007) 8(12):1705–13. doi: 10.2217/14626416.8.12.1705

23. Jin L, Chun J, Pan C, Alesi GN, Li D, Magliocca KR, et al. Phosphorylation-mediated activation of LDHA promotes cancer cell invasion and tumour metastasis. Oncogene (2017) 36(27):3797–806. doi: 10.1038/onc.2017.6

24. Rizwan A, Sanganova I, Khanin R, Karabehir E, Ni X, Thakur S, et al. Lactate and metastases in 4T1 breast tumors. Clin Cancer Research: an Off J Am Assoc Cancer Res (2013) 19(18):5158–69. doi: 10.1158/1078-0432.Ccr-12-3300

25. Jin H, Wang JF, Shao M, Zhou K, Ma X, Lv XP. Down-Regulation of miR-7 in Gastric Cancer Is Associated With Elevated LDH-A Expression and Chemoresistance to Cisplatin. Front Cell Dev Biol (2020) 8:555937. doi: 10.3389/fcell.2020.555937

26. Koukourakis MI, Kakouratos C, Bampali Z, Mavropoulou S, Sivridis E, et al. Hypoxia-inducible proteins HIF1α and lactate dehydrogenase LDH5, key markers of anaerobic metabolism, relate with stem cell markers and poor post-radiotherapy outcome in bladder cancer. Int J Radiat Biol (2016) 92(7):353–63. doi: 10.3109/09553002.2016.1162921

AUTHOR CONTRIBUTIONS

JW was involved in the design, data collection, and writing. YL and XQ were taking part in conception and revision. KY and CC were involved in conception, data analysis, writing, and revision. All remaining authors took part in data collection and writing. All authors contributed to the article and approved the submitted version.

ETHICS STATEMENT

The studies involving human participants were reviewed and approved by the Institutional Review Board at Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University. Written informed consent for participation was not required for this study in accordance with the national legislation and the institutional requirements.
27. Seth P, Czitromda E, Hedblom A, Vuerich M, Xie H, Li M, et al. Deletion of Lactate Dehydrogenase-A in Myeloid Cells Triggers Antitumor Immunity. Cancer Res (2017) 77(13):3632–43. doi: 10.1158/0008-5472.Can-16-2938.

28. Van Wijpe S, Koornstra R, Den Brok M, De Groot JW, Blank C, De Vries J, et al. Lactate dehydrogenase: a marker of diminished antitumor immunity. Oncoimmunology (2020) 9(1):1731942. doi: 10.1080/2162402X.2020.1731942.

29. Ding J, Karp JE, Emadi A. Elevated lactate dehydrogenase (LDH) can be a marker of immune suppression in cancer: Interplay between hematologic and solid neoplastic clones and their microenvironments. Cancer Biomarkers: Section A Dis Markers (2017) 19(4):353–63. doi: 10.3233/ibm-160336.

30. Faloppi L, Del Prete M, Casadei Gardini A, Santini D, Silvestris N, Bianconi M, et al. The correlation between LDH serum levels and clinical outcome in advanced biliary tract cancer patients treated with first line chemotherapy. Sci Rep (2016) 6:24136. doi: 10.1038/srep24136.

31. Deng T, Zhang J, Meng Y, Zhou Y, Li W. Higher pretreatment serum lactate dehydrogenase concentration predicts worse overall survival in patients with lung cancer. Medicine (2018) 97(38):e12524. doi: 10.1097/md.00000000000012524.

32. Sagman U, Feld R, Evans WK, Warr D, Shepherd FA, Payne D, et al. The prognostic significance of pretreatment serum lactate dehydrogenase in patients with small-cell lung cancer. J Clin Oncol: Off J Am Soc Clin Oncol (1991) 9(6):954–61. doi: 10.1092/jco.1991.9.6.954.

33. Petrelli F, Cabiddu M, Coinu A, Borgonovo K, Ghilardi M, Lonati V, et al. Lactate dehydrogenase (LDH) response to first-line treatment: Predictive Survival in Metastatic Breast Cancer: First Clues for A Cost-Effective and Dynamic Biomarker. Cancers (2019) 11(9):1243. doi: 10.3390/cancers11091243.

34. Namikawa T, Ishida N, Tsuda S, Fujisawa K, Munekage E, Iwabu J, et al. Prognostic significance of serum alkaline phosphatase and lactate dehydrogenase levels in patients with unrespectable advanced gastric cancer. Gastric Cancer: Off J Int Gastric Cancer Assoc Japanese Gastric Cancer Assoc (2019) 22(4):684–91. doi: 10.1007/s10120-018-0897-8.

35. Kostakis ID, Vaiopoulos AG, Philippou A, Papavassiliou AG, Koutsilieris M, Koutsilieris E, et al. The impact of elevated serum lactate dehydrogenase concentration predicts worse overall survival in patients with lung cancer. Head and Neck Dissection Clin Oncol (2019) 22(4):684. doi: 10.3109/0284186x.2015.1043026 – 606. doi: 10.1158/1078-0432.Ccr-13-2407.

36. Petrelli F, Cabiddu M, Coinu A, Borgonovo K, Ghilardi M, Lonati V, et al. Prognostic role of lactate dehydrogenase in patients with Squamous-cell lung cancer. Anticancer Res: Official Journal of the Association of Cancer Research and the Fund ‘Raffaella Barberis’ (2016) 36(3):131. doi: 10.21873/anticanres.8865.

37. Kostakis ID, Vaiopoulos AG, Philippou A, Papavassiliou AG, Koutsilieris M, Koutsilieris E, et al. The impact of elevated serum lactate dehydrogenase concentration predicts worse overall survival in patients with lung cancer. Head and Neck Dissection Clin Oncol (2019) 22(4):684. doi: 10.3109/0284186x.2015.1043026 – 606. doi: 10.1158/1078-0432.Ccr-13-2407.

38. Petrelli F, Cabiddu M, Coinu A, Borgonovo K, Ghilardi M, Lonati V, et al. Prognostic role of lactate dehydrogenase in solid tumors: a systematic review and meta-analysis of 76 studies. Prognostic role of lactate dehydrogenase in solid tumors: a systematic review and meta-analysis. Biomarkers Med (2013) 7(1):1863. doi: 10.2217/bmm.12.86.

39. Petrelli F, Cabiddu M, Coinu A, Borgonovo K, Ghilardi M, Lonati V, et al. Prognostic role of lactate dehydrogenase in solid tumors: a systematic review and meta-analysis of 76 studies. Prognostic role of lactate dehydrogenase in solid tumors: a systematic review and meta-analysis. Biomarkers Med (2013) 7(1):1863. doi: 10.2217/bmm.12.86.

40. Wu et al. LDH Predicts Hypopharyngeal Cancer Outcomes.
62. Cui J, Wang L, Piao J, Huang H, Chen W, Chen Z, et al. Initial surgical versus non-surgical treatments for advanced hypopharyngeal cancer: A meta-analysis with trial sequential analysis. *Int J Surg (London England)* (2020) 82:249–59. doi: 10.1016/j.ijsu.2020.04.059

63. Kılıç S, Kılıç SS, Hsueh WD, Eloy JA, Baredes S, Woo Park RC, et al. Radiotherapy modality as a predictor of survival in hypopharyngeal cancer. *Head Neck* (2018) 40(11):2441–8. doi: 10.1002/hed.25360

64. Sakaguchi M, Maebayashi T, Aizawa T, Ishibashi N, Saito T. Clinical Outcomes of Hypopharyngeal Cancer Receiving Definitive Radiotherapy with Concurrent Chemotherapy. *Anticancer Res* (2017) 37(2):941–7. doi: 10.21873/anticancerres.11403

**Conflict of Interest:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2021 Wu, You, Chen, Zhong, Mo, Song, Qiu and Liu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.